Feb 26, 2026 08:00AM
Jan 9, 2026 11:29AM
Jan 9, 2026 09:29AM
Dec 4, 2025 08:15AM
Dec 4, 2025 08:15AM
Nov 4, 2025 08:00AM
Aug 8, 2025 07:45AM Heron Therapeutics completes $212.7 million capital restructuring
Aug 8, 2025 07:45AM
Aug 8, 2025 07:45AM
May 6, 2025 07:45AM
Feb 27, 2025 07:45AM
Dec 3, 2024 04:43PM
Dec 3, 2024 04:36PM
Nov 12, 2024 07:55AM Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Oct 10, 2024 04:08PM
Sep 25, 2024 08:02AM
Sep 25, 2024 08:00AM
Aug 6, 2024 04:05PM
Jul 15, 2024 08:00AM
Jul 2, 2024 08:00AM
May 29, 2024 08:17AM Heron Therapeutics (HRTX) Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle
May 29, 2024 08:05AM
May 7, 2024 08:00AM
Mar 12, 2024 04:05PM
Jan 24, 2024 04:23AM
Jan 23, 2024 08:00PM
Jan 8, 2024 05:23AM
Jan 7, 2024 05:00PM Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
Dec 22, 2023 04:48PM
Nov 14, 2023 04:05PM
Aug 14, 2023 04:05PM
May 11, 2023 04:01PM
Apr 20, 2023 09:00AM
Apr 3, 2023 09:03AM
Apr 3, 2023 09:00AM Heron Therapeutics Announces New CEO and Board Chairman
Mar 23, 2023 04:05PM
Mar 13, 2023 09:00AM
Mar 6, 2023 09:02AM
Mar 6, 2023 09:00AM
Feb 22, 2023 09:00AM
Jan 9, 2023 08:30AM
Dec 29, 2022 09:01AM Heron Therapeutics (HRTX) Announces Filing of an Efficacy Supplement for ZYNRELEF, Provision in Newly Passed Bill Anticipated to Provide Separate Reimbursement Outside of Packaged Surgical Payment
Dec 29, 2022 09:00AM
Nov 8, 2022 04:05PM
Sep 16, 2022 03:09PM
Sep 16, 2022 02:49PM
Aug 9, 2022 08:01AM
Aug 9, 2022 08:01AM
Aug 9, 2022 08:00AM Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
Jun 30, 2022 12:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All